Year None20262025202420232022202120202019 Aug 07, 2026 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 05, 2026 Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update Jul 16, 2026 Arcutis Expands Board of Directors with Appointment of Chris Peetz Jul 15, 2026 Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 Jul 08, 2026 FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Jul 02, 2026 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 30, 2026 Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with C Jun 29, 2026 FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Chil Jun 05, 2026 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 9 of 31